MYC and diffuse large B-cell lymphoma: International multicentre, randomised phase III clinical trials have shown that BCL2 overexpression or c‐Myc and BCL2 co‐overexpression (double hits)15 was significantly associated with poor clinical outcomes and high relapse/refractory rates in patients with DLBCL and was an independent prognostic biomarker for evaluating overall and progression‐free survival of patients with DLBCL following R‐CHOP treatment.16